๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Cancer
Clinical trial register · India

Breast Cancer Trials in India, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
Nashik 10 Mumbai 9 Bangalore 8 Kolkata 8 Pune 7
Narrow the registerReset
Recruitment status
Phase
Site location
Nashik10 Mumbai9 Bangalore8 Kolkata8 Pune7
All 45 locations
Target enrolment
to

Breast Cancer trials in India

20 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
Nuvastaticยฎ Phase III Trial for Fatigue in Triple-Negative Breast Cancer
NCT07669467Fatigue Related to Cancer Treatment, Breast Cancer
Natureceuticals Sdn Bhd
Phase 3
250
Visakhapatnam, Mysore, Jalgaon, Pune, Erode, Kanpur
2025-10-01
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Active, closed
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
NCT06429761BREAST CANCER
AstraZeneca
Phase 4
100
Bangalore, Delhi, Kochi, Mumbai, New Delhi, Pune, Varanasi
2025-01-02
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
Tolmar Inc.
Phase 3
250
Surat, Bangalore, Bengaluru, Mysore, Nagpur, Nashik, Pune, Erode
2022-12-28
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
Celcuity Inc
Phase 3
701
Jaipur, Bangalore, Chandigarh, Kolkata, Navi Mumbai, Vellore
2022-12-08
Active, closed
To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer
NCT05969314Breast Cancer, Oral Cancer
Tata Memorial Hospital
Phase 1
12
Mumbai
2022-06-08
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Gurgaon, Howrah, Nagpur, Nashik, New Delhi, Raipur, Rishikesh, Surat
2021-10-25
Recruiting
Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD)
NCT05450016Breast Cancer
Tata Memorial Centre
Observational
720
Mumbai
2021-10-04
Active, closed
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395Breast Cancer
Tolmar Inc.
Phase 3
250
Vijayawada, Visakhapatnam, Ahmedabad, Surat, Bengaluru, Mysore, Nagpur, Nashik
2021-07-01
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
Hoffmann-La Roche
Phase 3
1,188
Ahmedabad, Bangalore, Mumbai, Nashik, Pune, New Delhi, North WEST Delhi, Ratnagiri Kilminnal
2021-05-04
Recruiting
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).
NCT04472845Breast Cancer, Hypofractionation, Radiotherapy Side Effect
Post Graduate Institute of Medical Education and Research, Chandigarh
Not applicable
1,018
Chandigarh
2021-03-30
Active, closed
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
NCT03946202Breast Cancer
Institute of Cancer Research, United Kingdom
Phase 2
184
Trivandrum, Vellore, Kolkata, Mumbai
2020-06-16
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Hyderabad, Ahmedabad, Vadodara, Gurgaon, Bangalore, Trivandrum, Mumbai, Nashik
2017-07-12
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566Breast Cancer
Eli Lilly and Company
Phase 3
463
Ahmedabad, Bangalore, Mumbai, Pune, New Delhi, Ranipet, Kolkata
2016-12-05
Active, closed
Comparison of Fulvestrant (FASLODEXโ„ข) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
AstraZeneca
Phase 3
736
Ansฤrinagar, Bhopal, Hyderabad, Jaipur, Kolkata, Manipal, Marg Jaipur, Mumbai
2005-02-13
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/condition/breast-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Breast Cancer.

How many Breast Cancer trials are recruiting in India?

5 of the 20 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Cancer), 20 studies
PhaseStudiesRecruitingShare
Phase 315375%
Not applicable115%
Observational115%
Phase 1105%
Phase 2105%
Phase 4105%

Most active sponsors

Lead sponsors with the most studies (Breast Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca71
Eli Lilly and Company20
Pfizer21
Tolmar Inc.20
Celcuity Inc10
Hoffmann-La Roche10
Institute of Cancer Research, United Kingdom10
Natureceuticals Sdn Bhd11
Post Graduate Institute of Medical Education and Research, Chandigarh11
Tata Memorial Centre11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.